Erika Cecchin

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

Jesse J. Swen, Cathelijne H. van der Wouden, Lisanne E. N. Manson et al. · The Lancet · 2023 · 462 citations · Full text

Drug Safety, Adverse Drug Reactions, Pharmacoepidemiology +9

The Role of UGT1A1*28 Polymorphism in the Pharmacodynamics and Pharmacokinetics of Irinotecan in Patients With Metastatic Colorectal Cancer

Giuseppe Toffoli, Erika Cecchin, Giuseppe Corona et al. · Journal of Clinical Oncology · 2006 · 333 citations · Full text

Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium

Cathelijne H. van der Wouden, Anne Cambon‐Thomsen, Erika Cecchin et al. · Clinical Pharmacology & Therapeutics · 2016 · 288 citations · Full text

Relevant Pgx-markers, Genetic Epidemiology, Ubiquitous Pharmacogenomics +22

Predictive Role of the <i>UGT1A1</i>, <i>UGT1A7</i>, and <i>UGT1A9</i> Genetic Variants and Their Haplotypes on the Outcome of Metastatic Colorectal Cancer Patients Treated With Fluorouracil, Leucovorin, and Irinotecan

Erika Cecchin, Federico Innocenti, Mario D’Andrea et al. · Journal of Clinical Oncology · 2009 · 215 citations · Full text

Genetics, Genetic Epidemiology, Pathology +16

Genotype-Driven Phase I Study of Irinotecan Administered in Combination With Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer

Giuseppe Toffoli, Erika Cecchin, Giampiero Gasparini et al. · Journal of Clinical Oncology · 2009 · 167 citations

Pharmacotherapy, Irinotecan Administered, Infusional Fluorouracil +16